Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $158.9 million.

  • BridgeBio Pharma's Non-Current Assets fell 2791.8% to $158.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $711.9 million, marking a year-over-year increase of 3350.46%. This contributed to the annual value of $198.6 million for FY2024, which is 18878.42% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Non-Current Assets is $158.9 million, which was down 2791.8% from $167.9 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Non-Current Assets high stood at $220.4 million for Q3 2024, and its period low was $65.9 million during Q1 2024.
  • Its 5-year average for Non-Current Assets is $125.8 million, with a median of $123.9 million in 2021.
  • As far as peak fluctuations go, BridgeBio Pharma's Non-Current Assets surged by 29641.27% in 2021, and later plummeted by 4700.17% in 2022.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Non-Current Assets stood at $123.9 million in 2021, then crashed by 40.14% to $74.2 million in 2022, then fell by 7.27% to $68.8 million in 2023, then soared by 188.78% to $198.6 million in 2024, then dropped by 20.02% to $158.9 million in 2025.
  • Its Non-Current Assets stands at $158.9 million for Q3 2025, versus $167.9 million for Q2 2025 and $186.5 million for Q1 2025.